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1022MP-163 Long-Term Adherence to Evidence-Based Therapies for 
Coronary Artery Disease and Heart Failure in the 
Outpatient Setting 
Nancy M. Allen LaPointe, Judith M Kramer, Bradley G. Hammill, Anita Chen, Elizabeth 
Ft. DeLong, Richeille K. Ricketts. Lawrence H. Muhlbaier, Charles 9. M&ants, Robert M. 
Califf. Duke Clinical Research Institute, Durham, NC 
Background: Previous studies have documented low use of evidence-based therapies 
for coronary artery disease (CAD) and heart failure (HF) at hospital discharge. Few stud- 
ies have evaluated the extent of use of these therapies after discharge. We evaluated 
long term use of evidence-based therapies in CAD and HF. 
Methods Patients who were referred to Duke Medical Center for a cardiac procedure 
and had CAD or HF were identified in the Duke Databank for Cardiovascular Disease. 
Follow-up surveys of these patients in their communities collect patient-reported medica- 
tion use annually. From 1995 to 2000 we determined annual prevalence of use of aspinn, 
beta-blockers (BE), and lipid lowering therapy (LLT) in patients with CAD; and use of 
beta-blockers and ACE inhibitors (ACEI) in patients with HF. Use of ACEI in patients with 
CAD but without HF was also determined. In addition to determinmg annual prevalence 
for each drug. we assessed consistency of use from 1995 to 2000 in individual patients. 
Results: Reported use of evidence-based therapies for CAD and HF increased from 
1995 to 2000. Of 20187 CAD patients in the year 2000, 81%. 46%, and 55%, reported 
use of aspirin, BB, and LLT, respectively. Only 27% reported taking all three drugs and 
41% reported taking aspirin plus BB. Of the 15037 patients with CAD and no HF, 28% 
reported ACEI use. Of 4971 HF patients I” 2000. 45% and 44% reported use of ACEI 
and 99, respectwely; 23% took both drugs. Over the years 1995-2000 in 27088 CAD 
patients, consistent use was lower: 57%, 30%, and 26%. for aspirin, BB, and LLT, 
respectively. Nine percent consistently took all three drugs. and 22% consistently took 
aspirin plus BB. Of the 19432 CAD patients without HF, 12% reported consistent ACEI 
use. Of the 7329 HF patients, only 26% reported consistent use of ACEI and 98, and 8% 
reported takmg both drugs. 
Conclusion: Efforts to improve the use of evidence-based therapies at hospital dls- 
charge are needed, but attention also needs to focus on improving long term adherence. 
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1022MP-164 Cost-Effectiveness Analysis of a Disease Management 
Proaram in Chronic Heart Failure: DIAL Trial-- 
G.E&.C.A. Investigators 
Huao 0. Grancelli, Caroia Zambrano, Ricardo D. Dran, Silvina Ramos, Saul Soifer. 
Armando Buso. Daniel Ferrante. Sergio Varini, Daniel Nul, Heman C. Doval, 
G.E.S.I.C.A. Foundation, Buenos Aires, Argentina 
Background: The impact of chronic heart failure (CHF) disease management programs 
in health costs remains uncertain, and no formal cost-effactweness analysis has been 
performed yet. 
Methods D.I.A.L. trial is a randomized multicentric controlled study to compare frequent 
telephomc fllow-up intevention versus (vs) usual cars in patients (pt) with CHF. The pri- 
mary oblective was to determine the effect of the intervention on all-cause mortality or 
heart failure hospitalization. A cost-effectiveness analysis was performed: 1) Costs: total 
hospitalizations, ambulatory and program direct costs; 2) Effectiveness: one-year sur- 
vival; 3) Time horizon: one year. The information concerning raso~rces use and costs 
was obtamed prospectively; 4) Sensibility analyses were performed. 
Results Between May 2000 and November 2001, 1519 pt with stable CHF were ran- 
domized (761 program, 758 control). 1) Annual mean costs per pt: program group 
required lower admission costs: 685 vs 827 US& p<O.Ol; lower cost per intensive care 
unit : 728 vs 842 US& pcO.01; lower cost for invasive procedures: 282 YS 400 US$, 
pc0.001. Both groups had similar costs for ambulatory care: 73.7 and 72 US$ for pro- 
gram and control groups. respectively (p=O.4). but the cost of drug treatment was signlfi- 
cantly greater in the program group (578 vs 477 US$, pcO.01) 2) Effectiveness: although 
no significant difference was detected in one-year suwival (91 .I program vs 90.1, 
RR=0.95, p=O.78), number of admissions for worsening of HF was significantly lower in 
the program group (RR=0.67, p=O.O04). as well as total admissions with a non-significant 
benefit for the same group (RR=0.87, p=O.O9). All admissions were included as resource 
use, not as effect. 3) We performed a cost-minimization analysis because the effective- 
ness was similar. Total mean costs par pt were: 2437 US$ for program vs 2618, with a 
difference of 181 US$ (Cl 95% [19-3421. p=O.O2). The results were not affected by differ- 
ent sensibility analyses. 
Conclusions This CHF disease management program allowed a significant reduction in 
hospitalization costs due to fewer admissions for worsening of HF as well as of total 
admissions. 
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Comorbidity Increases Health Care Expenditures and 
Physician Utilization in Elderly Patients With Chronic 
Heart Failure 
Joel B. Braunsteiq Gary Gerstenblith, Albert Wu, Gerard F. Anderson, Johns Hopkins 
Medical institutions, Baltimore, MD 
Introduction: The incidence and prevalence of chronic heart failure (CHF) are rising in 
the U.S., particularly in the elderly. Despite extensive comorbidity in this group, little is 
known about the impact of comorbidity on the economic and physician utilization burdens 
of CHF in these patients. 
Methods: We calculated total Medicare expenditures for each beneficwy and the num- 
ber of outpatient physician visits in 1999 in a 5% nationally representatwe sample of fee- 
for-service Medicare beneficiaries with chronic heart failure. We also assessed the incre- 
mental costs and physician utilization associated with each additional comorbidity based 
on ICD-9 coding?., after adjusting for patients’ age, gender, race, primary provider type, 
and mortality dunng 1999. 
Results: For the 122,620 patients in our sample, the mean age was 79.6 years. 88% 
wars white, and 60% were female. Mean Medicare par capita total expenditures were 
$17,091. Although patients with 10 or more comorbidities accounted for only 11% of the 
total sample, they accounted for 28% of total expenditures: with a mean of $43,439 par 
beneficiary. The median number of outpatient physician visits par beneficiary was 17.9. 
25% of patients made 23 or more outpatient physician visits and 10% made 34 or more. 
Beneficiaries with 5 or more comorbidities accounted for 73% of total outpatient visits 
during the year. After adjustment, each comorbidity associated with 53.668 in incremen- 
tal expenditures and 2.2 in incremental outpatient visits. 
Conclusion: Among CHF patients, extensive comorbidity accounts for disproportion- 
ately high Medicare expenditures and physician utilization. Disease management strate- 
gles targeting elderly CHF patients should focus on the population with extensive 
comorbidities to realize the greatest cost savings and service utilization benefits. 
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1022MP-166 Heart Failure Survival Score Continues to Predict Death 
or UNOS 1 Transplant in Heart Failure Patients 
Receiving Beta-Blockers 
Todd M. Koelling, Susan Joseph.Keith D. Aaronson, University of Michigan, Ann Arbor, 
Ml 
Background: The Heart Failure Survival Score (HFSS) effectively risk stratifies patients 
for heart transplant (HT). HT can be deferred in low risk HFSS patients; patients with 
HFSS in the moderate and high-risk subgroups are offered HT. However, the HFSS was 
developed prior to broad use of beta blockade (99). We hypothesized that HFSS would 
retain its ability to risk stratify HT need in BB patlents. Methods: We collected clinical data 
on 500 consecutive patients referred for HT from 1994 to 2002. including BB and the 7 
components of the HFSS: LVEF, peak V02, mean arterial BP, resting heart rate, QRS 
interval, serum sodium and CAD. Kaplan-M&r survival analysis with log rank testing 
and multivariable Cox regression analysis were performed with the events defined as 
death or UNOS 1 HT. Results: Kaplan-Meier analysis of the patient population (age 
51+1 I, male 73%, CAD 53%, ejection fraction 2li9%, peak V02 15.8+5.1 mllminlkg, 
HFSS 8.02*1.02 [low risk>=8.10]) revealed effective discrimination by HFSS both for BB 
and no BB patients (both p<O.OOOl). Two-year event free survival was 96+2% and 
87*3% for BB and no BB patients in the low-risk HFSS strata. Cox proportional hazards 
modeling showed that both BB (RR 0.48, p = 0.0001) and the HFSS (p c 0.0001) at the 
time of HT evaluatwn were independently associated with event-free survival. Conclu- 
sion: HFSS provides effective risk stratification with or without 99. Consideration of BB 
therapy with HFSS strata improves outcome predictlon in patients evaluated for HT. 
